Comparative Pharmacology
Head-to-head clinical analysis: ASBRON versus XOPENEX HFA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ASBRON versus XOPENEX HFA.
ASBRON vs XOPENEX HFA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Asbron is a combination product containing theophylline and guaifenesin. Theophylline is a methylxanthine that inhibits phosphodiesterase, leading to increased intracellular cAMP levels, resulting in bronchodilation and anti-inflammatory effects. Guaifenesin is an expectorant that increases respiratory tract fluid secretions to reduce mucus viscosity.
Selective beta-2 adrenergic receptor agonist; relaxes bronchial smooth muscle by increasing intracellular cyclic AMP via activation of adenylyl cyclase.
1-2 tablets (130-260 mg theophylline equivalent) orally every 6-8 hours; maximum 6 tablets/day.
2 inhalations (90 mcg each) every 4-6 hours as needed via oral inhalation. Maximum 12 inhalations per 24 hours.
None Documented
None Documented
4-6 hours in adults; prolonged to 8-12 hours in hepatic impairment or elderly patients
Terminal elimination half-life: 3-4 hours; clinical context: dosing every 4-6 hours for bronchodilation
Primarily renal (70-80% as unchanged drug), biliary/fecal (~15-20% as metabolites and unchanged drug)
Renal: 80-100% as unchanged drug and metabolites; fecal: minimal (<5%)
Category C
Category C
Bronchodilator
Bronchodilator